249.77
price up icon0.12%   0.31
after-market After Hours: 249.51 -0.26 -0.10%
loading
Beigene Ltd Adr stock is traded at $249.77, with a volume of 321.20K. It is up +0.12% in the last 24 hours and down -6.59% over the past month. Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
See More
Previous Close:
$249.46
Open:
$249.09
24h Volume:
321.20K
Relative Volume:
0.66
Market Cap:
$27.24B
Revenue:
$3.81B
Net Income/Loss:
$-644.79M
P/E Ratio:
-40.03
EPS:
-6.24
Net Cash Flow:
$-669.77M
1W Performance:
-1.19%
1M Performance:
-6.59%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$246.04
$250.29
1-Week Range:
Value
$244.40
$259.98
52-Week Range:
Value
$172.67
$287.88

Beigene Ltd Adr Stock (ONC) Company Profile

Name
Name
Beigene Ltd Adr
Name
Phone
13459494123
Name
Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Name
Employee
11,000
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ONC's Discussions on Twitter

Compare ONC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ONC
Beigene Ltd Adr
249.77 27.24B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
503.50 126.09B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
568.91 64.01B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
629.51 36.63B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
257.19 30.64B 2.25B -278.16M -42.59M -2.17

Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-07-25 Initiated RBC Capital Mkts Outperform
Mar-03-25 Upgrade BofA Securities Neutral → Buy
Dec-03-24 Resumed Morgan Stanley Overweight
Sep-18-24 Initiated JMP Securities Mkt Outperform
Feb-06-24 Resumed JP Morgan Overweight
Sep-12-23 Initiated Macquarie Outperform
Aug-17-23 Initiated Jefferies Buy
Jul-17-23 Initiated Citigroup Buy
Jun-30-23 Downgrade Bernstein Outperform → Mkt Perform
Jan-12-23 Initiated Daiwa Securities Buy
Oct-13-22 Upgrade Guggenheim Neutral → Buy
Oct-13-22 Upgrade SVB Leerink Mkt Perform → Outperform
Aug-09-22 Resumed JP Morgan Overweight
Mar-17-22 Downgrade SVB Leerink Outperform → Mkt Perform
Feb-07-22 Initiated Deutsche Bank Buy
Oct-12-21 Initiated Bernstein Outperform
Oct-06-21 Upgrade CLSA Underperform → Buy
Mar-08-21 Initiated China Renaissance Buy
Mar-01-21 Downgrade CLSA Outperform → Underperform
Nov-09-20 Downgrade Ladenburg Thalmann Buy → Neutral
Nov-06-20 Downgrade Maxim Group Buy → Hold
Nov-06-20 Downgrade Piper Sandler Neutral → Underweight
View All

Beigene Ltd Adr Stock (ONC) Latest News

pulisher
07:09 AM

BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India

07:09 AM
pulisher
06:19 AM

BeiGene wins US patent dispute over cancer drug - Investing.com

06:19 AM
pulisher
Apr 28, 2025

BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa

Apr 28, 2025
pulisher
Apr 28, 2025

BeiGene reports financial results under PRC GAAP - Investing.com

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 24, 2025

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance

Apr 24, 2025
pulisher
Apr 23, 2025

Why Summit Therapeutics Rocketed Double-Digits Today - The Motley Fool

Apr 23, 2025
pulisher
Apr 21, 2025

BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com

Apr 21, 2025
pulisher
Apr 17, 2025

BGNE Page Not Found - Benzinga

Apr 17, 2025
pulisher
Apr 16, 2025

Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India

Apr 16, 2025
pulisher
Apr 16, 2025

Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 10, 2025

Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com

Apr 10, 2025
pulisher
Apr 07, 2025

RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com

Apr 07, 2025
pulisher
Apr 04, 2025

JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India

Apr 03, 2025
pulisher
Mar 31, 2025

Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com

Mar 31, 2025
pulisher
Mar 20, 2025

Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India

Mar 20, 2025
pulisher
Mar 18, 2025

Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com

Mar 18, 2025
pulisher
Mar 13, 2025

Bernstein raises BeiGene stock price target to $259 - Investing.com

Mar 13, 2025
pulisher
Mar 12, 2025

BeiGene CEO John Oyler sells $10 million in shares - Investing.com India

Mar 12, 2025
pulisher
Mar 08, 2025

Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa

Mar 08, 2025
pulisher
Mar 08, 2025

Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India

Mar 08, 2025
pulisher
Mar 08, 2025

BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise

Mar 08, 2025
pulisher
Mar 07, 2025

Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Beigene CEO John Oyler sells $10.39 million in shares - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India

Mar 06, 2025
pulisher
Mar 04, 2025

Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com

Mar 04, 2025
pulisher
Mar 03, 2025

JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Beigene SVP sells $331,375 in American depositary shares - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

BofA lifts BeiGene stock rating, raises target to $320 By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 01, 2025

Beigene directors Julian and Felix Baker sell $190m in shares - Investing.com India

Mar 01, 2025
pulisher
Feb 28, 2025

BeiGene gets FDA Orphan Drug Designation for sonrotocla - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Guggenheim lifts BeiGene stock target to $348, maintains Buy rating - Investing.com India

Feb 28, 2025
pulisher
Feb 28, 2025

Citizens JMP lifts BeiGene stock target to $348 on strong sales By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Citizens JMP lifts BeiGene stock target to $348 on strong sales - Investing.com India

Feb 28, 2025
pulisher
Feb 27, 2025

AASTOCKS Financial NewsBeiGene, Ltd. (ONC) - AASTOCKS.com

Feb 27, 2025
pulisher
Feb 27, 2025

UBS Lifts BEIGENE (06160.HK) TP to $330, Rating Buy - AASTOCKS.com

Feb 27, 2025
pulisher
Feb 27, 2025

BeiGene stock price target raised to $334 at TD Cowen By Investing.com - Investing.com South Africa

Feb 27, 2025

Beigene Ltd Adr Stock (ONC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$104.00
price up icon 0.00%
$257.19
price up icon 0.92%
$23.62
price down icon 2.03%
$629.51
price up icon 1.38%
$32.71
price up icon 0.52%
Cap:     |  Volume (24h):